---
title: "Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Product information and disease description"
description: "Formulary evidence on Zipalertinib (CLN-081, TAS6417) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Product information and disease description. Covers Product description and Place of product in therapy. 57 evidence topics quoted from 57 sources."
canonical: "https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “Zipalertinib is investigational and has not been approved by any health authority.”

Source: [Taiho Oncology REZILIENT3 presidential symposium announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/)

<a id="topic-2.1.1-2"></a>

##### FDA submission initiation

> “Nov. 20, 2025”
> “the companies have initiated the rolling submission of a New Drug Application (NDA)”

Source: [Taiho Oncology rolling new drug application submission announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-e/)

<a id="topic-2.1.1-3"></a>

##### Regulatory status: Under review; NDA submitted February 2026

> “In February 2026”
> “Taiho completed a rolling submission of a new drug application (“NDA”) seeking accelerated approval of zipalertinib”

Source: [Cullinan Therapeutics annual report (2026)](https://materials.proxyvote.com/Approved/230031/20260420/AR_632667.PDF)

<a id="topic-2.1.1-4"></a>

##### FDA acceptance date

> “April 28, 2026”

Source: [Taiho Oncology new drug application acceptance announcement (2026)](https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/)

<a id="topic-2.1.1-5"></a>

##### FDA acceptance

> “has accepted a New Drug Application (NDA) for zipalertinib”

Source: [Taiho Oncology new drug application acceptance announcement (2026)](https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/)

<a id="topic-2.1.1-6"></a>

##### Anticipated FDA action date

> “PDUFA target action date of February 27, 2027”

Source: [Cullinan Therapeutics](https://cullinantherapeutics.com/science/pipeline/)

<a id="topic-2.1.1-7"></a>

##### Special FDA designation: initial announcement

> “has granted Breakthrough Therapy Designation for CLN-081”

Source: [Cullinan Therapeutics (2022)](https://investors.cullinantherapeutics.com/node/7366/pdf)

<a id="topic-2.1.1-8"></a>

##### Special FDA designation: later historical description

> “Zipalertinib previously received Breakthrough Therapy Designation in 2021”

Source: [Taiho Oncology rolling new drug application submission announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-e/)

<a id="topic-2.1.1-9"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-10"></a>

##### Product launch date and FDA Advisory Committee meeting

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Taiho Oncology

> “Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc.”

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer name

> “Taiho Oncology, Inc.”
> “Taiho Pharmaceutical Co., Ltd.”
> “Cullinan Therapeutics, Inc.”

Source: [Cullinan Therapeutics](https://cullinantherapeutics.com/science/pipeline/)

<a id="topic-2.1.2.1-3"></a>

###### Unapproved product name

> “Zipalertinib (development code: CLN-081/TAS6417)”

Source: [Taiho Oncology REZILIENT1 phase 2b primary endpoint announcement (2025)](https://www.taihooncology.com/us/news/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Commercial dosage forms, strengths, storage, and handling

No evidence found.

<a id="topic-2.1.2.2-2"></a>

###### Research reagent: not a clinical dosage form

> “WARNING: This product is for research use only, not for human or veterinary use.”

Source: [MedKoo Biosciences](https://www.medkoo.com/products/34604)

<a id="topic-2.1.2.2-3"></a>

###### Research reagent safety data sheet

| SDS information element | Direct quotation |
| --- | --- |
| Product name | “Zipalertinib” |
| Product catalogue number | “207108” |
| CAS number | “1661854-97-2” |
| Identified uses | “Laboratory chemicals, Synthesis of substances.” |
| Revision date | “5/20/2022” |

Source: [MedKoo Biosciences safety data sheet (2022)](https://www.medkoo.com/uploads/product/Zipalertinib/safety/SDS-Zipalertinib.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Investigational formulation in the adjuvant protocol

> “orally as tablets”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Drug class

> “next generation, irreversible EGFR inhibitor”

Source: [Taiho Oncology REZILIENT1 phase 2b primary endpoint announcement (2025)](https://www.taihooncology.com/us/news/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy/)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Prior-treatment population in the application

> “after platinum-based chemotherapy, with or without amivantamab.”

Source: [Taiho Oncology new drug application acceptance announcement (2026)](https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed mechanism of action

> “next generation, irreversible EGFR inhibitor”

Source: [Taiho Oncology REZILIENT1 phase 2b primary endpoint announcement (2025)](https://www.taihooncology.com/us/news/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy/)

<a id="topic-2.1.2.6.1-2"></a>

###### Covalent binding site

> “where it covalently modifies C797”

Source: [Cullinan Therapeutics annual report (2026)](https://materials.proxyvote.com/Approved/230031/20260420/AR_632667.PDF)

Additional sources: [Hasako et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29748209/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical selectivity

> “selectivity indexes (wild-type EGFR/mutant EGFR ratio of inhibition) favored TAS6417 in comparison with poziotinib and osimertinib”

Source: [Udagawa et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6872223/)

Additional sources: [Hamada et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37666482/); [Kagawa et al. (2023)](https://www.sciencedirect.com/science/article/pii/S2666364323000012)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics

> “The elimination half-life of zipalertinib is 3-4 hours after repeat twice-a-day dosing for 14 days.”

Source: [Piotrowska et al. (2023)](https://cullinantherapeutics.com/publications/safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patients-with-non-small-cell-lung-cancer-harboring-epidermal-growth-factor-receptor-exon-20-insertions-2023-jco/)

<a id="topic-2.1.2.6.3-2"></a>

###### Time to peak concentration after fasting administration

> “(Tmax) was in the range of 0.5-1.5 hours”

Source: [Piotrowska et al. (2023)](https://cullinantherapeutics.com/publications/safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patients-with-non-small-cell-lung-cancer-harboring-epidermal-growth-factor-receptor-exon-20-insertions-2023-jco/)

Additional sources: [Dixit and Das (2025)](https://pubmed.ncbi.nlm.nih.gov/41099528/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Trial eligibility: organ function

> “Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.”

Source: [National Cancer Institute NCI-2023-10904](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10904)

<a id="topic-2.1.2.8-2"></a>

###### Renal and hepatic dose adjustments

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Zipalertinib

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Zipalertinib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Drug-drug interaction substudy

> “For DDI substudy, participants will be enrolled in two groups:”
> “CYP Cocktail Group”
> “Transporter Cocktail Group”

Source: [National Cancer Institute NCI-2023-10904](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10904)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Investigational monotherapy dosage

> “100 mg BID oral”

Source: [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Food instructions in the updated trial presentation

> “Zipalertinib may be taken with or without food.”

Source: [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercialization

> “Taiho will commercialize zipalertinib.”

Source: [Cullinan Therapeutics annual report (2026)](https://materials.proxyvote.com/Approved/230031/20260420/AR_632667.PDF)

<a id="topic-2.1.2.11-2"></a>

###### Pre-approval access: Taiho’s general expanded-access policy

> “Taiho accepts requests for pre‑approval access to investigational cancer medicines from physicians only.”
> “does not guarantee access to any investigational product.”

Source: [Taiho Oncology expanded access policy](https://www.taihooncology.com/us/science/expanded-access/)

<a id="topic-2.1.2.11-3"></a>

###### Anticipated commercial distribution strategy and patient support programs

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### First-line combination studied in REZILIENT3

> “platinum-pemetrexed chemotherapy”

Source: [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Zipalertinib on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

Additional sources: [Aggarwal and Liu (2023)](https://pubmed.ncbi.nlm.nih.gov/37487151/); [Dempke et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12838662/); [Lau et al. (2026)](https://link.springer.com/article/10.1007/s40265-026-02329-7); [Miyamura et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12452814/); [Xie et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40337604/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Molecularly defined disease subset

> “EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations”

Source: [Riess et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6764748/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of EGFR exon 20 insertion-mutated non-small-cell lung cancer

<a id="topic-2.2.1.2.1-1"></a>

###### U.S. annual incidence per 100,000 for the anticipated indication

No evidence found.

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of EGFR exon 20 insertion-mutated non-small-cell lung cancer

<a id="topic-2.2.1.2.2-1"></a>

###### Frequency in a genomic-profiling series

> “Of 14,483 NSCLC cases, CGP identified 263 (1.8%) cases with EGFRex20ins, representing 12% (263/2,251) of cases with EGFR mutations.”

Source: [Riess et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6764748/)

<a id="topic-2.2.1.2.2-2"></a>

###### U.S. population prevalence per 100,000 for the anticipated indication

No evidence found.

Additional sources: [Burnett et al. (2021)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0247620)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history: clinical characteristics and prognosis

> “Patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but a poorer prognosis.”

Source: [Oxnard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3549533/)

<a id="topic-2.2.1.3-2"></a>

###### Real-world outcomes: overall survival versus common EGFR mutations

> “The median (95% CI) rwOS was 16.2 (11.04-19.38) months in the EGFR exon20ins cohort vs 25.5 (24.48-27.04) months in the cEGFR cohort”

Source: [Bazhenova et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34818606/)

Additional sources: [Ou et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37744306/); [Behera et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38827378/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “When people have an EGFR mutation, the EGFR protein on their cells can trigger cancer growth.”

Source: [Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/cancer-care/clinical-trials/24-026)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic testing and underdiagnosis

> “An analysis of variants projected that ~ 50% of EGFR ex20ins identified by NGS would have been missed by PCR-based assays.”

Source: [Viteri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9892822/)

<a id="topic-2.2.1.5-2"></a>

###### Guideline preference for multiplex molecular testing

> “If available, multiplex platforms (NGS) for molecular testing are preferable”

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

Additional sources: [Lin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8851244/); [Ou et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36738930/); [Vidal et al. (2024)](https://doi.org/10.1200/OP.23.00253); [Lin et al. (2025)](https://academic.oup.com/oncolo/article-pdf/30/5/oyaf067/63126928/oyaf067.pdf)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Constitutional and pain symptoms in the exon 20 insertion population

> “One conference abstract described the symptom burden for Exon 20ins patients with fatigue and pain being most common.”

Source: [Burnett et al. (2021)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0247620)

Additional sources: [Horn et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8474204/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### CNS involvement in the REZILIENT1 safety population, n (%)

> “103 (42)”

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of EGFR exon 20 insertion-mutated non-small-cell lung cancer

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Systematic literature review: scope of the burden evidence

> “Seventy-eight unique studies were included; 53 reporting mutation frequency, 13 prognostic impact, 36 clinical outcomes, and one humanistic burden.”

Source: [Burnett et al. (2021)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0247620)

Additional sources: [Horn et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8474204/); [Paz-Ares et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41671629/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Amivantamab treatment patterns and health care resource utilization

> “Mean outpatient service use was 5.87 days PPPM before amivantamab initiation and 6.79 days PPPM during amivantamab treatment.”

Source: [Waterhouse et al. (2026)](https://link.springer.com/article/10.1186/s12890-026-04334-8)

<a id="topic-2.2.1.8.2-2"></a>

###### Amivantamab plus chemotherapy economic model

> “A partitioned survival model was developed based on the data from the PAPILLON trial.”
> “Amivantamab plus chemotherapy yielded an additional 1.12 quality-adjusted life years (QALYs) while increasing costs by $483,769.50 relative to the chemotherapy regimen, leading to an ICER of $432,401.16/QALY.”
> “The combination of amivantamab with chemotherapy was not cost effective at a threshold of $150,000/QALY.”
> “Amivantamab plus chemotherapy is unlikely to be a cost-effective option for NSCLC patients with EGFR exon 20 insertions. Reducing the cost of amivantamab may produce favorable economic outcomes.”

Source: [Cao et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38990458/)

Additional sources: [Vadagam et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38269536/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of EGFR exon 20 insertion-mutated non-small-cell lung cancer on Families

Not applicable.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 EGFR-MET Bispecific Antibodies

<a id="topic-2.2.2.1.1-1"></a>

###### Pan-Asian adapted ESMO guideline

> “Amivantamab combined with platinum-based ChT is recommended for the treatment of EGFR exon 20 insertion-mutated NSCLC in the first-line setting”

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="topic-2.2.2.1.1-2"></a>

###### Comparator regulatory information: amivantamab

> “approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment”
> “traditional approval to amivantamab-vmjw”

Source: [FDA (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications)

<a id="topic-2.2.2.1.1-3"></a>

###### First-line amivantamab plus chemotherapy: progression-free survival and response

> “Progression-free survival was significantly longer in the amivantamab–chemotherapy group than in the chemotherapy group (median, 11.4 months and 6.7 months, respectively; hazard ratio for disease progression or death, 0.40; 95% confidence interval [CI], 0.30 to 0.53; P<0.001).”
> “At 18 months, progression-free survival was reported in 31% of the patients in the amivantamab–chemotherapy group and in 3% in the chemotherapy group; a complete or partial response at data cutoff was reported in 73% and 47%, respectively (rate ratio, 1.50; 95% CI, 1.32 to 1.68; P<0.001).”
> “In the interim overall survival analysis (33% maturity), the hazard ratio for death for amivantamab–chemotherapy as compared with chemotherapy was 0.67 (95% CI, 0.42 to 1.09; P=0.11).”

Source: [Zhou et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37870976/)

<a id="topic-2.2.2.1.1-4"></a>

###### First-line amivantamab plus chemotherapy: toxicity and treatment discontinuation

> “The predominant adverse events associated with amivantamab–chemotherapy were reversible hematologic and EGFR-related toxic effects; 7% of patients discontinued amivantamab owing to adverse reactions.”
> “The incidence of infusion-related reactions was 42% in the amivantamab–chemotherapy group and 1% in the chemotherapy group.”
> “The most common grade 3 or higher adverse events were neutropenia (in 33%), leukopenia (in 11%), and rash (in 11%) with amivantamab–chemotherapy and neutropenia (in 23%), anemia (in 12%), and thrombocytopenia (in 10%) with chemotherapy.”
> “Serious adverse events were reported in 37% of the patients in the amivantamab–chemotherapy group and in 31% of those in the chemotherapy group”

Source: [Zhou et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37870976/)

Additional sources: [Park et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8791812/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 EGFR Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Comparator regulatory information: sunvozertinib

> “granted accelerated approval to sunvozertinib”
> “on or after platinum-based chemotherapy.”
> “200 mg orally once daily with food”

Source: [FDA (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20)

<a id="topic-2.2.2.1.2-2"></a>

###### Treatment alternatives: sunvozertinib, WU-KONG1B

> “Sunvozertinib is efficacious at both 200 and 300 mg once daily in treating platinum-pretreated patients with advanced EGFR exon20ins NSCLC.”

Source: [Yang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40923280/)

<a id="topic-2.2.2.1.2-3"></a>

###### Treatment alternatives: first-line sunvozertinib, WU-KONG28

> “The percentage of patients with an objective response was 58.9% in the sunvozertinib group and 31.1% in the chemotherapy group”

Source: [Zhou et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42212913/)

Additional sources: [Jänne et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39879577/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### Platinum-pemetrexed backbone in the approved first-line combination

> “approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment”

Source: [FDA (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications)

Additional sources: [Kwon et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35621011/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Surgery

<a id="topic-2.2.2.1.4-1"></a>

###### Local therapy for selected oligometastatic disease

> “surgery”

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Radiotherapy

<a id="topic-2.2.2.1.5-1"></a>

###### Local therapy for selected oligometastatic disease

> “high-dose RT”

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Supportive and Palliative Care

<a id="topic-2.2.2.1.6-1"></a>

###### Palliative care alongside oncologic treatment

> “Early palliative care intervention is recommended”

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

Amivantamab with platinum-based chemotherapy is recommended for first-line treatment, and sunvozertinib has accelerated approval after platinum-based chemotherapy. Activity in one line of treatment does not establish comparative effectiveness in another. WU-KONG28 reported objective responses in 58.9% with sunvozertinib and 31.1% with chemotherapy. The evidence assembled here does not provide a randomized comparison of Zipalertinib against amivantamab-containing therapy or sunvozertinib.

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/); [FDA (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20); [Zhou et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42212913/); [Taiho Oncology ASCO 2025 REZILIENT1 results announcement (2025)](https://www.taihooncology.com/us/news/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology-to-present-positive-results-from-pivotal-phase-2b-rezilient1-trial-of-zipalertinib-at-asco-2025/); [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

Additional sources: [Puri et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02822)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The proposed post-platinum use includes participants previously treated with or without amivantamab. REZILIENT1 evaluates oral monotherapy, whereas REZILIENT3 evaluates first-line Zipalertinib with platinum-pemetrexed chemotherapy. These regimens and populations should be considered separately. Pre-approval access requests must come from physicians and do not guarantee access.

Source: [Taiho Oncology new drug application acceptance announcement (2026)](https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/); [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf); [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html); [Taiho Oncology expanded access policy](https://www.taihooncology.com/us/science/expanded-access/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Zipalertinib clinical resistance case report

> “After eight months of treatment with CLN081, liquid biopsy revealed the emergence of a secondary EGFR C797S mutation”

Source: [Dabbah et al. (2026)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1812440/full)

<a id="topic-2.2.2.3-2"></a>

###### Diversity of exon 20 insertion variants

> “Sixty-four unique EGFRex20ins were identified”

Source: [Riess et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6764748/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Guideline follow-up interval

> “Follow-up every 8-12 weeks”

Source: [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Observed monotherapy outcomes after prior platinum-based chemotherapy

> “In patients treated after prior platinum-based chemotherapy only (n=125), ORR was 40% with mDOR of 8.8 months.”

Source: [Taiho Oncology REZILIENT1 Journal of Clinical Oncology publication announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology/)

## Related pages
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical evidence](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: References](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
